

# UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/992,235	11/06/2001	Seth Lederman	2516-1-002N	5392
23565 7	7590 08/25/2003			
KLAUBER & JACKSON			EXAMINER	
411 HACKENSACK AVENUE HACKENSACK, NJ 07601			DELACROIX MUI	RHEI, CYBILLE
			ART UNIT	PAPER NUMBER
			1614	
			DATE MAILED: 08/25/2003	7

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/992,235	LEDERMAN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Cybille Delacroix-Muirheid	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on <u>05 N</u>	March 2003					
,	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-22 is/are pending in the application						
4a) Of the above claim(s) is/are withdraw	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)⊠ Claim(s) <u>1-8</u> is/are allowed.						
6)⊠ Claim(s) <u>9-20 and 22</u> is/are rejected.						
7)⊠ Claim(s) <u>21</u> is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	•					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received.  15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	/ (PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/992,235

Art Unit: 1614

### **Detailed Action**

The following is responsive to Applicant's amendment received March 5, 2003.

No claims are cancelled. No new claims are added. Claims 1-22 are currently pending.

The previous rejection of claims 1-8 under 35 USC 103(a) over Wolter et al. 5,462,746 or Midha et al., 6,217,904, maintained in the office action mailed Dec. 3, 2002, **is withdrawn** in view of Applicant's amendment and the remarks contained therein.

The previous rejection of claims 9-22 under 35 USC 103(a) over Midha et al., supra in view of Wolter et al., supra, maintained in the office action mailed Dec. 3, 2002, is withdrawn in view of Applicant's amendment and the remarks contained therein.

The previous claims rejection under 35 USC 112, paragraph1, set forth at paragraph 4 of the office action mailed Dec. 3, 2002, **is withdrawn** in view of Applicant's amendment and the remarks contained therein.

However, upon further consideration, the Examiner respectfully submits that claim 9 raises an additional issue, which is addressed below.

## **New Ground of Rejection**

## Claim Rejections - 35 USC § 112

1. Claims 9-20 and 22 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims are

Application/Control Number: 09/992,235

Art Unit: 1614

drawn to a method of treating a "human condition or disease requiring or benefiting from a central nervous system stimulant" comprising administering to a human in need thereof an effective amount of a composition comprising (R,R')(R,S')-amphetaminil sulfate substantially free of (S,R')(S,S')-amphetaminil. The claimed method of treatment fails to meet the requirement for an adequate written description of the claimed invention as required by 35 USC, 112, paragraph 1. There is insufficient descriptive support for the generic limitation "human condition or disease requiring or benefiting from a central nervous system stimulant." Furthermore, the claimed method requires treatment of an unspecified disease and no evidence indicates that a treatable disease, other than those listed at pages 3-4 of the specification, was known to Applicant. In the absence of some understanding of other diseases to be treated, one of ordinary skill in the art would not have concluded that Applicant was in possession of the claimed method.

2. Claim 21 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### Allowable Subject Matter

Claims 1-8 are free from the prior art because the prior art does not teach or fairly suggest Applicant's claimed pharmaceutical composition.

#### Conclusion

Claims 1-8 are allowable.

Claim 9-20 and 22 are rejected.

Application/Control Number: 09/992,235

Art Unit: 1614

Claim 21 is objected to.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cybille Delacroix-Muirheid whose telephone number is 703-306-3227. The examiner can normally be reached on Tue-Thur. from 8:30 to 6:00. The examiner can also be reached on alternate Mondays.

Page 4

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel, can be reached on (703) 308-4725 The fax phone number for the organization where this application or proceeding is assigned is 703-308-7924.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

August 20, 2003

Cybille Delacroix-Muirheld